Table 5.
Mean scores and standard deviation (SD) for the considered scale in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and symptom scale rash, as well as absolute and relative frequencies for Patient Health Questionnaire-4 (PHQ-4) considered for the analysis. Differences in mean scores and proportions, as well as 95% confidence intervals (CI) of the estimates, are reported for group comparison
| Quality of life and symptom scales | Group Aa | Group Bb | Group Cc | Difference in mean scores | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Between groups A and B | Between groups A and C | Between groups B and C | |||||||||||||||
| Mean | SD | Mean | SD | Mean | SD | Estimate | 95% CI | Estimate | 95% CI | Estimate | 95% CI | ||||||
| Lower | Upper | Lower | Upper | Lower | Upper | ||||||||||||
| Global quality of life | 57.1 | 21.4 | 68.8 | 22.8 | 57.5 | 24.6 | − 11.7 | − 19.19 | − 4.21 | − 0.4 | − 7.56 | 6.76 | 11.3 | 6.47 | 16.13 | ||
| Physical functioning | 61.1 | 28.1 | 64.0 | 24.5 | 62.3 | 24.7 | − 2.9 | − 11.45 | 5.65 | − 1.2 | − 8.56 | 6.16 | 1.7 | − 3.21 | 6.61 | ||
| Fatigue | 50.0 | 30.8 | 48.6 | 28.8 | 48.3 | 29.0 | 1.4 | − 8.42 | 11.22 | 1.7 | − 6.88 | 10.28 | 0.3 | − 5.47 | 6.07 | ||
| Nausea and vomiting | 13.2 | 23.3 | 8.1 | 19.1 | 8.4 | 16.2 | 5.1 | − 1.72 | 11.92 | 4.8 | − 0.19 | 9.79 | − 0.3 | − 3.65 | 3.05 | ||
| Pain | 32.7 | 34.2 | 29.3 | 31.8 | 31.2 | 32.9 | 3.4 | − 7.47 | 14.27 | 1.5 | − 8.21 | 11.21 | − 1.9 | − 8.41 | 4.61 | ||
| Appetite loss | 29.9 | 37.8 | 20.7 | 30.4 | 18.5 | 28.3 | 9.2 | − 1.73 | 20.13 | 11.4 | 2.79 | 20.01 | 2.2 | − 3.52 | 7.92 | ||
| Diarrhoea | 33.3 | 37.0 | 7.7 | 17.2 | 13.7 | 25.7 | 25.6 | 17.39 | 33.80 | 19.6 | 11.31 | 27.89 | − 6.0 | − 11.07 | − 0.93 | ||
| Rash | 25.0 | 32.6 | 11.8 | 27.9 | 12.0 | 26.7 | 13.2 | 2.92 | 23.48 | 13.0 | 4.59 | 21.41 | − 0.2 | − 5.82 | 5.42 | ||
| Dyspnoea | 31.7 | 26.1 | 35.6 | 26.1 | 43.2 | 27.2 | − 3.9 | − 13.05 | 5.25 | − 11.5 | − 19.86 | − 3.14 | − 7.6 | − 13.23 | − 1.97 | ||
| PHQ-4 | Group Aa | Group Bb | Group Cc | Difference in proportions | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Between groups A and B | Between groups A and C | Between groups B and C | |||||||||||||||
| N | % | N | % | N | % | Estimate | 95% CI | Estimate | 95% CI | Estimate | 95% CI | ||||||
| Lower | Upper | Lower | Upper | Lower | Upper | ||||||||||||
| Depression | 6 | 12.2 | 23 | 19.0 | 104 | 21.0 | − 6.8 | − 18.33 | 4.73 | − 8.8 | − 18.64 | 1.04 | − 2.0 | − 9.86 | 5.86 | ||
| Anxiety | 6 | 12.2 | 18 | 14.9 | 90 | 18.3 | − 2.7 | − 13.85 | 8.45 | − 6.1 | − 15.88 | 3.68 | − 3.4 | − 10.60 | 3.80 | ||
aGroup A: N = 49, patients with confirmed RTK mutation, TKI treatment, and stage IV cancer at data assessment
bGroup B: N = 121, patients with no-RTK mutation, non-TKI treatment, and stage IV cancer at diagnosis or metastases
cGroup C: N = 495, patients with no-RTK mutation, non-TKI treatment, and stage I-III cancer at diagnosis, no metastases